Antifungal Prophylaxis for Hematologic Malignancies: Yuan Wan, MD, PhD

While antifungal prophylaxis can effectively prevent invasive fungal infections in patients with hematologic diseases, there is no consensus on which prophylactic agents provide the greatest benefit for different patient populations. In a meta-analysis recently published in JAMA Network Open, a team of researchers found that among antifungal prophylactic agents, posaconazole may be the best option for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), while voriconazo...
Continue reading

Antifungal Prophylaxis for Hematologic Malignancies: Which Agent Is Best?

In a meta-analysis evaluating the efficacy of prophylactic agents against invasive fungal infections (IFIs) for patients with hematological diseases, investigators found that posaconazole may be the best option for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), although voriconazole may be the best option for patients undergoing hematopoietic stem cell transplantation (HSCT). "Invasive fungal infections have emerged as important causes of morbidity and mortality i...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.